Is the treatment effect of IFN-β restored after the disappearance of neutralizing antibodies?

Abstract

Objective

To establish whether multiple sclerosis (MS) patients, who have lost the therapeutic effect of interferon-beta (IFN-β) owing to neutralizing antibodies (NAbs) and subsequently revert from a NAb-positive to a NAb-negative state under continued IFN-β-1b therapy, regain clinical effect after reversion.

Background

Several studies have shown that a significant proportion of patients treated with IFN-β develop NAbs that hamper or abolish the therapeutic effect of IFN-β. However, some patients, who become NAb-positive under treatment with IFN-β-1b, may revert to a NAb-negative state under continuous treatment.

Methods

We identified 40 patients from the Danish IFN protocol, who fulfilled the criteria: NAb-positive status for at least 12 months followed by reversion to NAb-negative state for at least 12 months. For comparison, we included 64 matching cases that had remained NAb-negative during an observation time of at least 36 months. The two groups were clinically and demographically alike. We measured NAb-neutralizing capacity using a clinically validated cytopathic effect assay. A blood sample with a neutralizing capacity of 20% or more was considered as NAb-positive. A patient was defined as NAb-positive after two consecutive blood tests separated by at least 6 months. Reversion to a NAb-negative state required at least two consecutive negative tests. To allow for the confounding effect of time we employed a mixed Poisson model.

Results

Patients who had been NAb-positive and reverted to a NAb-negative state regained treatment effect with the relapse rate as before the NAb-positive period adjusting for the effect of time, and the relapse rate was the same as in the permanently NAb-negative patients in corresponding time periods. The relapse rate ratio comparing the NAb-positive with the NAb-negative periods was 1.98 (95% confidence interval: 1.32–2.97).

Conclusion

Under NAb-positive periods, the clinical effect of IFN-β was abolished. When NAbs disappeared spontaneously under continued treatment, patients regained the full effect of INF-β-1b therapy with no negative carry-over effect from the previous NAb-positive period.

Keywords

interferon-beta interferon-beta antibodies multiple sclerosis neutralizing antibodies therapy treatment effect

Get full access to this article

View all access options for this article.

References

1 Ross C Clemmesen KM Svenson M Sorensen PS Koch-Henriksen N Skovgaard GL . for the Danish Multiple Sclerosis Study Group.

Immunogenicity of interferon-beta in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration.

Ann Neurol 2000; 48: 706 – 712 .

2 Perini P Facchinetti A Bulian P Massaro AR Pascalis DD Bertolotto A . Interferon-beta (INF-beta) antibodies in interferon-beta1a- and interferon-beta1b-treated multiple sclerosis patients. Prevalence, kinetics, cross-reactivity, and factors enhancing interferon-beta immunogenicity in vivo. Eur Cytokine Netw 2001; 12: 56 – 61 .

3 The IFNB Multiple Sclerosis Study Group . Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 655 – 661 .

4 The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group . Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. Neurology 1996; 47: 889 – 894 .

5 PRISMS Study Group . PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS. Neurology 2001; 56: 1628 – 1636 .

6 Francis GS Rice GP Alsop JC . Interferon beta-1a in MS: results following development of neutralizing antibodies in PRISMS. Neurology 2005; 65: 48 – 55 .

7 Polman C Kappos L White R Dahlke F Beckmann K Pozzilli C . Neutralizing antibodies during treatment of secondary progressive MS with interferon beta-1b. Neurology 2003; 60: 37 – 43 .

8 Panitch H Miller A Paty D Weinshenker B . Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology 2004; 63: 1788 – 1795 .

9 Sorensen PS Ross C Clemmesen KM Bendtzen K Frederiksen JL Jensen K . Clinical importance of neutralising antibodies against interferon beta in patients with relapsing–remitting multiple sclerosis. Lancet 2003; 362: 1184 – 1191 .

10.

10 Kappos L Clanet M Sandberg-Wollheim M Radue EW Hartung HP Hohlfeld R . Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study. Neurology 2005; 65: 40 – 47 .

11.

11 Sorensen PS Koch-Henriksen N Ross C Clemmesen KM Bendtzen K . Appearance and disappearance of neutralizing antibodies during interferon-beta therapy. Neurology 2005; 65: 33 – 39 .

12.

12 Bendtzen K . Anti-IFN BAb and NAb antibodies: a minireview. Neurology 2003; 61: S6 – 10 .

13.

13 Bertolotto A Gilli F Sala A Audano L Castello A Magliola U . Evaluation of bioavailability of three types of IFNbeta in multiple sclerosis patients by a new quantitative-competitive-PCR method for MxA quantification. J Immunol Methods 2001; 256: 141 – 152 .

14.

14 Bertolotto A Gilli F Sala A Capobianco M Malucchi S Milano E . Persistent neutralizing antibodies abolish the interferon beta bioavailability in MS patients. Neurology 2003; 60: 634 – 639 .

15.

15 Bertolotto A Sala A Malucchi S Marnetto F Caldano M Di Sapio A . Biological activity of interferon betas in patients with multiple sclerosis is affected by treatment regimen and neutralising antibodies. J Neurol Neurosurg Psychiatry 2004; 75: 1294 – 1299 .

16.

16 Cook SD Quinless JR Jotkowitz A Beaton P . Serum IFN neutralizing antibodies and neopterin levels in a cross- section of MS patients. Neurology 2001; 57: 1080 – 1084 .

17.

17 Deisenhammer F Reindl M Harvey J Gasse T Dilitz E Berger T . Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies. Neurology 1999; 52: 1239 – 1243 .

18.

18 Pachner AR Bertolotto A Deisenhammer F . Measurement of MxA mRNA or protein as a biomarker of IFNbeta bioactivity: detection of antibody-mediated decreased bioactivity (ADB). Neurology 2003; 61: S24 – S26 .

19.

19 Pachner AR Dail D Pak E Narayan K . The importance of measuring IFNbeta bioactivity: monitoring in MS patients and the effect of anti-IFNbeta antibodies. J Neuroimmunol 2005; 166: 180 – 188 .

20.

20 Rudick RA Simonian NA Alam JA Campion M Scaramucci JO Jones W . Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG). Neurology 1998; 50: 1266 – 1272 .

21.

21 Sorensen PS Tscherning T Mathiesen HK Langkilde AR Ross C Ravnborg M . Neutralizing antibodies hamper IFNbeta bioactivity and treatment effect on MRI in patients with MS. Neurology 2006; 67: 1681 – 1683 .

22.

22 Polman CH Kappos L Petkau J Thompson A . Neutralising antibodies to interferon beta during the treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry 2003; 74: 1162 – 1163 .

23.

23 Sorensen PS Deisenhammer F Duda P Hohlfeld R Myhr KM Palace J . Guidelines on use of anti-interferon-beta antibody measurements in multiple sclerosis––report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis. Eur J Neurol 2005; 12: 817 – 827 .

24.

24 Malucchi S Capobianco M Gilli F Marnetto F Caldano M Sala A . Fate of multiple sclerosis patients positive for neutralising antibodies towards interferon beta shifted to alternative treatments. Neurol Sci 2005; 26: S213 – S214 .

25.

25 Petkau AJ White R . Statistical approaches to assessing the effects of neutralizing antibodies: IFNbeta-1b in the pivotal trial of relapsing–remitting multiple sclerosis. Neurology 2003; 61: S35 – S37 .

26.

26 Petkau AJ White RA Ebers GC Reder AT Sibley WA Lublin FD . Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis. Mult Scler 2004; 10: 126 – 138 .

27.

27 Sorensen PS Koch-Henriksen N Ravnborg M Frederiksen JL Jensen K Heltberg A . Immunomodulatory treatment of multiple sclerosis in Denmark: a prospective nationwide survey. Mult Scler 2006; 12: 253 – 264 .

28.

28 Bellomi F Scagnolari C Tomassini V Gasperini C Paolillo A Pozzilli C . Fate of neutralizing and binding antibodies to IFN beta in MS patients treated with IFN beta for 6 years. J Neurol Sci 2003; 215: 3 – 8 .

29.

29 Gneiss C Reindl M Lutterotti A Ehling R Egg R Khalil M . Interferon-beta: the neutralizing antibody (NAb) titre predicts reversion to NAb negativity. Mult Scler 2004; 10: 507 – 510 .

30.

30 Sorensen PS Koch-Henriksen N Bendtzen K . Are ex vivo neutralising antibodies against IFN-β always detrimental to therapeutic efficacy in multiple sclerosis? Mult Scler 2007; 13: 616 – 621 .